Tags

Type your tag names separated by a space and hit enter

Advances in supportive care of patients with cancer and bone metastases: nursing implications of zoledronic acid.
Clin J Oncol Nurs. 2003 Jul-Aug; 7(4):403-8.CJ

Abstract

The knowledge and training of nursing staff is essential for the safety and comfort of patients receiving i.v. therapies. The use of i.v. bisphosphonates as an adjunct to standard antineoplastic therapies in patients with advanced cancer is becoming widespread. Zoledronic acid and pamidronate (Zometa and Aredia, Novartis Pharmaceuticals Corporation, East Hanover, NJ) are nitrogen-containing bisphosphonates. Pamidronate has been the standard of care for patients with osteolytic bone lesions from breast cancer or multiple myeloma. However, zoledronic acid, which has demonstrated increased potency and a broad clinical utility, is emerging as the new standard of care. In addition to treating hypercalcemia of malignancy, zoledronic acid is approved for treating patients with bone metastases (osteolytic or osteoblastic) from a wide range of solid tumors, including breast, prostate, and lung cancers, or osteolytic bone lesions from multiple myeloma. Zoledronic acid (4 mg via a 15-minute infusion) has a safety profile comparable with pamidronate (90 mg via a two-hour infusion) and has demonstrated comparable or superior efficacy to that of pamidronate in every patient population tested. The shorter infusion time of zoledronic acid compared with that of pamidronate may provide added convenience, but safety guidelines should be followed for all i.v. bisphosphonate therapies. These guidelines and nursing care of patients receiving i.v. bisphosphonates are reviewed.

Authors+Show Affiliations

cmaxwell@ohgsf.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

12929273

Citation

Maxwell, Cathy, et al. "Advances in Supportive Care of Patients With Cancer and Bone Metastases: Nursing Implications of Zoledronic Acid." Clinical Journal of Oncology Nursing, vol. 7, no. 4, 2003, pp. 403-8.
Maxwell C, Swift R, Goode M, et al. Advances in supportive care of patients with cancer and bone metastases: nursing implications of zoledronic acid. Clin J Oncol Nurs. 2003;7(4):403-8.
Maxwell, C., Swift, R., Goode, M., Doane, L., & Rogers, M. (2003). Advances in supportive care of patients with cancer and bone metastases: nursing implications of zoledronic acid. Clinical Journal of Oncology Nursing, 7(4), 403-8.
Maxwell C, et al. Advances in Supportive Care of Patients With Cancer and Bone Metastases: Nursing Implications of Zoledronic Acid. Clin J Oncol Nurs. 2003 Jul-Aug;7(4):403-8. PubMed PMID: 12929273.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Advances in supportive care of patients with cancer and bone metastases: nursing implications of zoledronic acid. AU - Maxwell,Cathy, AU - Swift,Regina, AU - Goode,Melissa, AU - Doane,Lois, AU - Rogers,Miriam, PY - 2003/8/22/pubmed PY - 2003/11/8/medline PY - 2003/8/22/entrez SP - 403 EP - 8 JF - Clinical journal of oncology nursing JO - Clin J Oncol Nurs VL - 7 IS - 4 N2 - The knowledge and training of nursing staff is essential for the safety and comfort of patients receiving i.v. therapies. The use of i.v. bisphosphonates as an adjunct to standard antineoplastic therapies in patients with advanced cancer is becoming widespread. Zoledronic acid and pamidronate (Zometa and Aredia, Novartis Pharmaceuticals Corporation, East Hanover, NJ) are nitrogen-containing bisphosphonates. Pamidronate has been the standard of care for patients with osteolytic bone lesions from breast cancer or multiple myeloma. However, zoledronic acid, which has demonstrated increased potency and a broad clinical utility, is emerging as the new standard of care. In addition to treating hypercalcemia of malignancy, zoledronic acid is approved for treating patients with bone metastases (osteolytic or osteoblastic) from a wide range of solid tumors, including breast, prostate, and lung cancers, or osteolytic bone lesions from multiple myeloma. Zoledronic acid (4 mg via a 15-minute infusion) has a safety profile comparable with pamidronate (90 mg via a two-hour infusion) and has demonstrated comparable or superior efficacy to that of pamidronate in every patient population tested. The shorter infusion time of zoledronic acid compared with that of pamidronate may provide added convenience, but safety guidelines should be followed for all i.v. bisphosphonate therapies. These guidelines and nursing care of patients receiving i.v. bisphosphonates are reviewed. SN - 1092-1095 UR - https://www.unboundmedicine.com/medline/citation/12929273/Advances_in_supportive_care_of_patients_with_cancer_and_bone_metastases:_nursing_implications_of_zoledronic_acid_ L2 - https://store.ons.org/article/find?doi=10.1188/03.CJON.403-408 DB - PRIME DP - Unbound Medicine ER -